(Q36199036)

12 August 2017

1 reference

title

Safety and tolerability of emerging pharmacological treatments for bipolar disorder (English)

1 reference

12 August 2017

1 reference

David L Dunner

1

1 reference

12 August 2017

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

307-325

1 reference

The expanding pharmacopoeia for bipolar disorder

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

What is a "mood stabilizer"? An evidence-based response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Suicide risk in bipolar disorder during treatment with lithium and divalproex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Clinical factors associated with treatment noncompliance in euthymic bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Mood stabilizer combinations: a review of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

New anticonvulsant medication uses in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

New antiepileptic drugs: review on drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Antipsychotic-induced weight gain: bipolar disorder and leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Menstrual cycle related mood changes in women with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Altered ovarian function and cardiovascular risk factors in valproate-treated women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Oral contraceptives reduce lamotrigine plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Use of topiramate in treatment-resistant bipolar spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Topiramate in Bipolar and Schizoaffective Disorders: Weight Loss and Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Newer antiepileptic drugs and cognitive issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

The effects of adjunctive topiramate on cognitive function in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Postmarketing experience with topiramate and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

An open label study of gabapentin in the treatment of acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Efficacy and safety of zonisamide: results of a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Tiagabine in treatment refractory bipolar disorder: a clinical case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Efficacy and safety of novel antipsychotics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Aripiprazole: profile on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Antipsychotic drugs in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Obesity as a correlate of outcome in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

The role of atypical antipsychotics in bipolar depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

New onset diabetes and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Olanzapine-induced diabetic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Severe weight gain induced by combination treatment with risperidone and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Clozapine in the treatment of refractory psychotic mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

The effect of alcohol and substance abuse on the course of bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Clozapine: a clinical review of adverse effects and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Combination treatment in bipolar disorder: a review of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Antidepressants for bipolar depression: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00235.X

10.1111/J.1399-5618.2005.00235.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference